Search

Search Constraints

You searched for: Author/Creator Sikorska, K

Search Results

1. 2022-RA-1451-ESGO Critical care management following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: not routinely indicated. (20th October 2022)

5. L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients. (1st October 2020)

6. LBA330 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial). (17th December 2018)

7. LBA42OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). (23rd October 2018)

8. LBA46Phase II study comparing pembrolizumab (PEM) with intermittent/short‐term dual MAPK pathway inhibition plus PEM in patients harboring the BRAFV600 mutation (IMPemBra). (23rd October 2018)